Icosavax Reports Positive 12-Month Durability Data for VLP Vaccine Candidate IVX-121
Icosavax Reports Positive 12-Month Durability Data for VLP Vaccine Candidate IVX-121
In new data from Icosavax's IVX-121 Phase 1b extension trial in older adults, GMTs against RSV through day 365 persisted at ~45-70% of the GMTs at day 28 (for 75 and 250 μg unadjuvanted dosages) -
在 Icosavax 针对老年人的 IVX-121 1b 期延期试验的新数据中，截至第 365 天，针对呼吸道合胞病毒的 GMT 在第 28 天持续在 GMT 的约 45-70%（75 和 250 微克未调整剂量）-
- Data provide additional clinical evidence of potential differentiation on durability with company's VLP platform technology -
-数据提供了额外的临床证据，证明公司的 VLP 平台技术在耐久性方面存在潜在差异-
- Robust immune response against RSV-A observed in Phase 1b extension trial participants who were revaccinated with IVX-121 twelve months following initial dose -
-在初始剂量十二个月后重新接种 IVX-121 疫苗的 1b 期延期试验参与者中观察到对 RSV-A 的强大免疫反应-
- IVX-121 continues to be generally well tolerated with no additional safety concerns observed with longer-term follow up or revaccination -
-IVX-121 总体耐受性仍然良好，长期随访或重新接种疫苗后不会出现其他安全问题-
- IVX-A12 (a potential-first-in-class bivalent combination of IVX-121 for RSV and IVX-241 for hMPV) currently in a Phase 2 trial; Phase 2 topline interim data now expected by end 2023 -
-IVX-A12（一种潜在的同类首创双价组合，用于呼吸道合胞病毒，IVX-241 用于呼吸道合胞病毒）目前正在进行二期试验；现在预计将在2023年底发布第二阶段的中期数据-IVX-121